image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

SIGN UP NOW
Updates

Alliance Pharma

June 2012

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • APH
  • Price:
  • 30p
Alliance Pharma, which owns a portfolio of branded generic medicines, reported slightly lower than expected full-year pretax profit of £10.7m (2010: £12.9m) with eps falling from 5.1p to 3.6p. The swing factor was a significant sales reduction for its previous best seller, Deltacortril, which fell off a cliff from an exceptional £13.5m to £4.7m, including just £1.1m in the second half, due to increased competition. However, to put this  hiatus into perspective total group sales last year were £46m, which is 47% higher than 2009. Another important point is that Deltacortril, which treats arthritic joints and bowel disease, only cost £1m to acquire but has generated £13m cash and this has been ploughed back into acquisi ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

Alliance Pharma (July 2013)
Alliance Pharma - Acquires new products (September 2012)
Alliance Pharma (November 2011)
Alliance Pharma - Cambridge Labs nehind its growth (June 2011)
Alliance Pharma (October 2010)
Alliance Pharma (August 2010)
Alliance Pharma - Trading ahead of expectations (July 2010)
Alliance Pharma - Gain reaches 75% in five months (May 2010)
Alliance Pharma - Substantial eps enhancing acquisition (March 2010)
Alliance Pharma - Beats expectations again (February 2010)
Alliance Pharma - Branded pharmaceuticals firm going great guns but cheap on PE of 6.7 (December 2009)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X